WeedMD (WMD.V) offers PAX ERA pod options to Starseed Medicinal clients

WeedMD (WMD.V) will start selling Pedro’s Sweet Sativa PAX ERA products to their Starseed Medicinal clients on March 6th, 2021, according to a press release.

The Starseed medicinal-branded oil pods use in-house produced cannabis-derived terpenes, which will be available for purchase through its online medical portal.

“In keeping with our long-standing tradition of releasing products first to our medical community, we’re thrilled to launch the PAX ERA line-up in our award-winning Pedro’s Sweet Sativa strain as the latest addition to our growing portfolio. With product features that offer an updated medical experience, our teams worked together over the past few months to finely curate this portfolio of vaporizer products using our premier, quality-produced, strain-specific biomass. We’re looking forward to expanding with additional terpene-rich strains such as Mango Haze and Black Sugar Rose, particularly as our next launch of concentrates will include our adult-use Color Cannabis-branded PAX ERA pods,” said George Scorsis, executive chairman and CEO.

WeedMD has two subsidiaries: WeedMD RX and Starseed Medicinal, which are licensed producers and distributors of cannabis for both the medicinal and adult-use markets. The company produces their cannabis out of a 158 acre greenhouse and outdoor processing facility in Strathroy, Ontario, and another 26,000 square foot processing facility in Aylmer, Ontario, that specializes in extraction.

PAX themselves have over two million devices sold worldwide and an established reputation as the best-selling pen and pod system in the United States. Their closed-loop PAX ERA pods are leak resistant and clog free. WeedMD is betting that the partnership with PAX will help accelerate their cannabis 2.0 product strategy as it expands its product and cultivation options.

Source: stockwatch.com

WeedMD is down $0.04 today, and presently trading at $0.54.

—Joseph Morton

More on

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments